使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主
Operator
Operator
Hello everyone. Thank you for joining us and welcome to the Corteva Agriscience third quarter 2026 earnings conference call. (Operator Instructions)
各位好。感謝各位加入我們,歡迎參加 Corteva Agriscience 2026 年第三季財報電話會議。(接線員指示)
I will now hand the conference over to Rafa Soares, Head of Investor Relations. Rafa, please go ahead.
我現在把會議交給投資人關係主管 Rafa Soares。Rafa,請開始。
Rafael Soares - Head of Investor Relations
Rafael Soares - Head of Investor Relations
Good morning and welcome to Corteva's third quarter 2026 Earnings Conference Call. Our prepared remarks today will be led by Luca Sam, Chief Executive Officer; and Jeff Rudolph, Chief Financial Officer. We have prepared presentation slides to supplement our remarks during this call, which are posted on the Investor Relations section of the Corteva website and through the link to our webcast.
各位早安,歡迎參加 Corteva 2026 年第三季財報電話會議。今天的準備發言將由執行長 Luca Sam 與財務長 Jeff Rudolph 主講。我們已準備簡報投影片以補充本次電話會議的發言內容,投影片已張貼於 Corteva 官網的投資人關係專區,亦可透過網路直播連結取得。
During this call, we'll make forward-looking statements, which are expectations about the future. These statements are based upon current expectations and assumptions that are subject to various risks and uncertainties.
在本次電話會議中,我們將作出前瞻性陳述,也就是對未來的預期。這些陳述係基於目前的預期與假設,並可能受到各種風險與不確定性影響。
Our actual results could materially differ from these statements due to these risks and uncertainties, including but not limited to those discussed on this call and in the risk factors section of our reports filed with the SEC.
由於上述風險與不確定性(包括但不限於本次電話會議所討論者,以及我們向美國證券交易委員會(SEC)提交之報告中的風險因素章節所載者),我們的實際結果可能與這些陳述存在重大差異。
We do not undertake any duty to update any forward-looking statements. Please note, in today's presentations, we will be making reference to certain non-GAAP financial measures. EBITDA means adjusted pro forma operating EBITDA and sales refers to pro forma net sales.
我們不承擔更新任何前瞻性陳述的義務。請注意,在今天的簡報中,我們將提及若干非 GAAP 財務衡量指標。EBITDA 指調整後備考營運 EBITDA,而銷售額指備考淨銷售額。
Reconciliations of the non-GAAP measures can be found in our earnings press release. And related sketches along with our supplemental financial summaries like DAC available on our Investor Relations website.
非 GAAP 指標的調節表可見於我們的財報新聞稿。相關附表以及我們的補充財務摘要(如 DAC)亦可於投資人關係網站取得。
It's now my pleasure to turn the call over to Luke.
現在我很高興把電話會議交給 Luke。
Luther Kissam - Chief Executive Officer
Luther Kissam - Chief Executive Officer
Thanks, Rafa, and good morning, everybody. Thanks for joining us. This is our first earnings call as a stand-alone company, so I want to start with the strategy we laid out at our recent Investor Day and how it played out in the quarter.
謝謝你,Rafa,各位早安。感謝各位加入我們。這是我們作為獨立公司後的第一次財報電話會議,因此我想先談談我們在近期投資人日所提出的策略,以及該策略在本季的落實情況。
In September, we said this chapter would be defined by innovation and execution. This quarter gave us clear proof points on both. The exception to that is Brazil, which I will unpack a bit more in a moment. Starting with innovation, new product volumes grew 20% in the quarter with growth in every region and price was relatively stable for this group of products.
我們在 9 月表示,這一章將以創新與執行力為核心。本季在這兩方面都提供了明確的佐證。例外是巴西,我稍後會再多做說明。先談創新:本季新產品銷量成長 20%,各區域皆有成長,而這一組產品的價格相對穩定。
Our business outside of Latin America performed roughly in line with expectations in a challenge operating environment. We generated growth across North America, EMEA and Asia Pacific. While pricing was down 12% in North America in the quarter, all of that headwind was caused by pricing actions related to acetochlor, which we forewarned at Investor Day.
在具挑戰的營運環境下,我們在拉丁美洲以外的業務表現大致符合預期。我們在北美、EMEA 與亞太地區均實現成長。雖然本季北美定價下滑 12%,但所有不利影響皆源自與乙草氯(acetochlor)相關的定價行動,我們在投資人日已事先提醒。
Productivity came in ahead of our expectations in the quarter, and we were on track to deliver our target for the year. We also brought SG&A spending down in the quarter as teams exercised good discipline on spend relative to our operating environment. And even as we took cost out, we increased our investment in R&D to keep advancing our pipeline, which is one of the real strengths of this company.
本季生產力表現優於我們的預期,我們也正按計畫達成全年目標。同時,團隊在支出方面相對於營運環境展現良好紀律,使本季 SG&A 支出下降。即便我們降低成本,我們仍提高研發投資以持續推進產品管線,這也是本公司真正的優勢之一。
Through the first nine months of the year, we've maintained operating EBITDA levels flat to prior year and expanded EBITDA margins despite absorbing approximately $230 million in pricing headwinds. On capital deployment, our Board declared our first quarterly dividend as a standalone company, which is an important aspect of our capital allocation priorities. We remain on track for our targeted year-end cash position of roughly $1.5 billion.
今年前九個月,我們在吸收約 2.30 億美元定價逆風的情況下,仍維持營運 EBITDA 與去年同期持平,並擴大 EBITDA 利潤率。在資本配置方面,董事會宣布我們作為獨立公司後的首度季度股利,這是我們資本配置優先事項的重要一環。我們仍按計畫在年底達成約 15 億美元的目標現金部位。
So a lot is going well, and it's aligned with the strategy we previously laid out. I'm encouraged by that, but Brazil is the exception, so let me spend a few minutes there. Brazil was already a difficult market, but grower economics, high interest rates. Currency impacts and El Nino weather patterns made a difficult market even more challenging.
因此,許多方面進展良好,且與我們先前提出的策略一致。我對此感到鼓舞,但巴西是例外,所以我想花幾分鐘談談。巴西原本就是困難的市場,但種植戶經濟狀況、高利率、匯率影響以及聖嬰現象(El Nino)的天氣型態,使得原本困難的市場更加艱鉅。
Market conditions deteriorated sharply in the final weeks of the third quarter, and we've continued to see negative development since then. Latin America organic sales were down 31% in the quarter, which more than offset the growth we delivered everywhere else. Uncertainty in that market remains elevated. We did not anticipate the magnitude nor the speed of the deterioration we have experienced in Brazil, and part of that was more specific to Corteva.
第三季最後幾週市場狀況急遽惡化,此後我們仍持續看到負面發展。拉丁美洲本季有機銷售額下滑 31%,其降幅超過我們在其他所有地區所帶來的成長。該市場的不確定性仍然偏高。我們未預期巴西惡化的幅度與速度,而其中一部分原因更是 Corteva 特有的情況。
While the September 30 market data would indicate that we are maintaining share on the farm this year, too much of the product we sold into the Brazil channel last year didn't go to ground. As a result, we came into this year with more of our own inventory in the channel than expected. And when purchasing slowed, that overhang created a bigger headwind for us. We own that, and we're taking steps to address the issue. So while I'm encouraged by the execution of our strategy in the quarter, the pressure in Brazil remains significant.
雖然截至 9 月 30 日的市場數據顯示我們今年在農場端仍維持市占,但我們去年銷往巴西通路的產品中,有太多並未真正到達田間使用。因此,我們在今年開始時,通路中屬於我們自有的庫存高於預期。當採購放緩時,這個庫存壓力對我們造成更大的逆風。我們承擔責任,並正採取措施解決此問題。因此,儘管我對本季策略執行感到鼓舞,但巴西的壓力仍然相當顯著。
Despite holding year-to-year EBITDA levels flat the prior year through the third quarter, we have adjusted our expectations for the full year due to what we are seeing in Brazil. Jeff will talk more about the specifics on guide shortly.
儘管截至第三季我們的 EBITDA 與去年同期持平,但基於我們在巴西所見情況,我們已調整對全年表現的預期。Jeff 稍後將更詳細說明財測的具體內容。
Now, let me turn to the market because it explains both sides of the story. The best word I have for this market is mixed. On the farm, demand is holding up. Applications remain pretty strong and growers are still focused on maximizing yield. However, in some areas, grower economics are under pressure and growers are being careful about what they spend and when they spend it.
接著我談談市場,因為它能解釋故事的兩面。我對這個市場最貼切的形容詞是「分歧」。在農場端,需求仍具韌性。施用量仍相當強勁,種植戶仍專注於最大化產量。然而,在某些地區,種植戶的經濟狀況承受壓力,因而對支出內容與支出時點更為謹慎。
The channel is doing the same thing. Distributors are managing working capital tightly and ordering is increasingly just in time. That's why you have to separate what's happening on the farm from what's happening in the purchase cycle. The demand is there. What has changed is when people buy and how much inventory they're willing to carry.
通路端也在做同樣的事。經銷商嚴格管理營運資金,訂貨愈來愈偏向即時(just in time)。因此,你必須把農場端正在發生的事與採購循環中正在發生的事分開看。需求仍在。改變的是人們何時購買,以及他們願意持有多少庫存。
Pricing is the other piece. The market remains competitive in older off-patent molecules. Pricing pressure is real, but as I have said previously, it's not new. How we anticipate and/or respond to those pricing pressures as we did in the quarter with respect to acetochlor in North America is what will matter longer-term.
定價是另一個面向。在較舊、已過專利期的分子產品上,市場競爭仍然激烈。價格壓力確實存在,但如我先前所說,這並非新現象。長期而言,關鍵在於我們如何預判及/或回應這些定價壓力,就像我們本季在北美針對乙草氯所採取的作法。
Where we have differentiated solutions, it's a totally different story. Products like Arylex, a multi-crop herbicide and Pyraxalt, an insecticide, have both experienced year-over-year volume growth north of 20%. And these are meaningful products with combined annual revenue of around $650 million.
而在我們具差異化解決方案的領域,情況則完全不同。例如 Arylex(多作物除草劑)與 Pyraxalt(殺蟲劑),兩者的銷量年增率皆超過 20%。而且這些都是重要產品,合計年營收約 6.5 億美元。
At the end of the day, the business performed in line with gross expectations everywhere other than Brazil. As a result, I'm even more convinced we have the right strategy. We need to address Brazil, and it's a top priority for me and the leadership team to find the best approach for Corteva relative to that market.
總結來說,除巴西以外,各地業務表現皆大致符合整體預期。因此,我更加確信我們的策略是正確的。我們需要處理巴西問題,對我與領導團隊而言,找出 Corteva 在該市場的最佳應對方式是最優先事項。
With that, I'll turn it over to Jeff for more details on the financials.
接下來我把時間交給 Jeff,請他提供更多財務細節。
Jeff Rudolph - Chief Financial Officer
Jeff Rudolph - Chief Financial Officer
Thanks, Luke, and welcome everyone to the call this morning. Let's start on slide 6, which provides our adjusted pro forma results for the third quarter and year-to-date. As Luke said, in many ways, we had two very different quarters. Solid execution against our plan across most of the world, and the Brazil market that got significantly worse. You'll see both in the numbers.
謝謝你,Luke,也歡迎各位今天早上加入電話會議。我們先看第 6 頁投影片,該頁提供我們第三季與年初至今的調整後備考結果。如 Luke 所說,從許多角度來看,我們經歷了兩個截然不同的季度。在全球大多數地區,我們依計畫穩健執行;而巴西市場則顯著惡化。你們將在數字中同時看到這兩者。
For the third quarter, net sales were $1.6 billion, down 9% versus the prior year on both a reported and organic basis. Operating EBITDA was $222 million, down 17%, and operating EBITDA margin was 14%, down 140 basis points.
第三季淨銷售額為16億美元,無論按申報口徑或有機口徑,均較去年同期下降9%。營運EBITDA為2.22億美元,下降17%,營運EBITDA利潤率為14%,下降140個基點。
Price was the largest headwind. It was concentrated in US acetochlor, which we anticipated and signal as part of our previous comments, and in Brazil where generics are pressuring several molecules late in their life cycle. On top of that, delayed purchasing in conjunction with elevated channel inventories in Brazil drove volumes sharply lower.
價格是最大的逆風。主要集中在美國的乙草氯(acetochlor),這點我們先前的評論中已預期並加以提示;以及巴西,當地學名藥正對多個處於產品生命週期後段的分子造成壓力。此外,巴西通路庫存偏高,加上採購延後,導致銷量大幅下滑。
Now what did not change was demand for our new technologies. New products grew in every region and productivity again ran ahead of our expectations. Together, with a modest benefit from currency, that offset a good part of the price pressure in the quarter.
不過,對我們新技術的需求並未改變。新產品在各區域皆成長,生產力表現再次超出我們預期。再加上匯率帶來的小幅助益,抵消了本季相當一部分的價格壓力。
Now focusing on year-to-date, net sales were $5.4 billion, down 1% compared to last year, and organic sales were down 4% on lower pricing. Operating EBITDA was $943 million, essentially flat with last year. And margins expanded by 30 basis points despite more than approximately $230 million of pricing headwinds.
聚焦年初至今,淨銷售額為54億美元,較去年下降1%;有機銷售額因價格較低而下降4%。營運EBITDA為9.43億美元,與去年基本持平。儘管面臨超過約2.3億美元的價格逆風,利潤率仍擴張30個基點。
New product growth, productivity and currency were significant benefits through the first nine months of the year. As we've laid out at our Investor Day, the combination of new products and productivity have largely been our algorithm for driving performance in the challenging market environment.
新產品成長、生產力提升與匯率因素,在今年前九個月帶來顯著助益。正如我們在投資人日所闡述,新產品與生產力的組合,基本上一直是我們在充滿挑戰的市場環境中推動績效的「演算法」。
Let's now go to slide 7, which breaks down net sales by region for the third quarter. This is where you can really see the two distinct outcomes for the quarter mentioned previously. First, we saw solid execution against our plan outside of Latin America. Our strategy is to deliver value for our customers and drive growth with new and differentiated technologies, and you can see that proof in the results.
接著請看第7頁投影片,該頁按地區拆解第三季淨銷售額。在這裡你可以清楚看到先前提到的本季兩種截然不同的結果。首先,在拉丁美洲以外,我們對照計畫的執行表現穩健。我們的策略是為客戶交付價值,並以新且具差異化的技術帶動成長,而結果也證明了這一點。
For example, North America sales were up 7% with volume up 19%. Early demand for our differentiated products drove those volume gains and more than offset lower price. As we signaled earlier this year, the anticipated price pressure was concentrated in acetochlor, which essentially drove all of the price headwind in North America.
例如,北美銷售額成長7%,銷量成長19%。對我們差異化產品的早期需求帶動了銷量成長,並且足以抵消較低的價格。如同我們今年稍早所提示,預期的價格壓力主要集中在乙草氯,幾乎造成北美所有的價格逆風。
Growers here remain focused on maximizing yield and return on investment, and application rates are healthy. EMEA grew 12% in the quarter or 14% on an organic basis. Volume was up 14%, driven by Arylex and early demand for seed treatment, and we held price flat in the competitive market.
當地種植戶仍專注於最大化產量與投資報酬率,施用率維持健康水準。EMEA本季成長12%,若按有機口徑則成長14%。銷量成長14%,由Arylex以及對種子處理產品的早期需求所帶動;在競爭激烈的市場中,我們維持價格持平。
We delivered a similar trend for the year-to-date performance with positive organic growth despite a challenging market backdrop due to weather-related impacts from dry and hot conditions across much of Europe. Asia Pacific grew 3% or 5% organically with volume up 7%. Demand for new products remained strong, and the team navigated difficult weather in several key markets, including India.
年初至今的表現也呈現類似趨勢:儘管市場背景充滿挑戰,且歐洲多地受乾燥與高溫等天候因素影響,我們仍實現有機正成長。亞太地區成長3%,按有機口徑成長5%,銷量成長7%。新產品需求依然強勁,團隊也在包括印度在內的多個關鍵市場中克服了不利天候。
Now, in contrast, Latin America was a very different outcome in the quarter. We knew coming in that it would be a difficult market, and it got harder as the quarter went on. Growers are dealing with weather impacts from El Nino and high interest rates and tight liquidity across the market, and the industry remains under heavy pressure from generics. With expensive credit and tight liquidity, growers and distributors delay their purchases, while we also work through our elevated channel inventories.
相較之下,拉丁美洲本季的結果截然不同。我們在進入本季前就知道這會是一個艱難的市場,而且隨著季度推進情況更為嚴峻。種植戶正面臨聖嬰現象帶來的天候影響、高利率以及市場整體流動性緊縮,而產業仍承受學名藥的沉重壓力。在信貸成本高昂且流動性吃緊的情況下,種植戶與經銷商延後採購;同時我們也在消化偏高的通路庫存。
For Latin America overall, this resulted in volume declines of 24% and price down 7%. The pressure intensified in the final days of September, and conditions have continued to move in the wrong direction since then.
就拉丁美洲整體而言,這導致銷量下滑24%,價格下降7%。壓力在9月最後幾天加劇,此後情勢仍持續朝不利方向發展。
So Latin America sales were down about $220 million, more than offsetting roughly $70 million of growth across the rest of the world. And Latin America was about 45% of our third quarter sales last year, so a decline of that size outweighs a lot of good work elsewhere.
因此,拉丁美洲銷售額約減少2.2億美元,遠超過全球其他地區合計約7,000萬美元的成長。而拉丁美洲去年約占我們第三季銷售額的45%,如此幅度的下滑足以抵消其他地區大量的良好成果。
Let's move to slide 8 and the operating EBITDA bridge for the quarter. Operating EBITDA was $222 million, down $46 million from last year. Price was the main driver, an approximate $120 million headwind in the quarter. And about 90% of that came from two areas, acetochlor in the US and generic pressure in Brazil concentrated in certain molecules.
接著請看第8頁投影片,本季營運EBITDA的橋接分析。營運EBITDA為2.22億美元,較去年減少4,600萬美元。價格是主要驅動因素,本季約有1.2億美元的逆風。其中約90%來自兩個領域:美國的乙草氯,以及巴西在特定分子上集中的學名藥壓力。
Volume had no net impact on EBITDA despite being a headwind to the top-line. Strong performance in North America, EMEA and Asia Pacific, including favorable mix, helped offset the decline in Latin America.
儘管銷量對營收端構成逆風,但對EBITDA的淨影響為零。北美、EMEA與亞太的強勁表現(包括有利的產品組合)有助於抵消拉丁美洲的下滑。
Moving to cost, the teams continue to execute well on items within our control, specifically cost of goods sold productivity and lower SG&A spending more than covered increased investments in R&D to advance our leading pipeline, resulting in a net benefit of $67 million for the quarter alone.
在成本方面,團隊持續在我們可控的項目上執行良好,特別是銷貨成本的生產力提升,以及較低的SG&A支出,已足以覆蓋為推進我們領先的研發管線而增加的研發投資,使本季單季淨受益達6,700萬美元。
Taking a step back, the bridge tells a similar story as the regional slide. The pressure is concentrated in a handful of molecules and one particular market. And the value drivers of our strategy, including new product penetration and productivity, are delivering.
退一步看,這份橋接分析與地區投影片傳達的故事相似。壓力集中在少數幾個分子與某一特定市場。而我們策略的價值驅動因素,包括新產品滲透與生產力提升,正在發揮成效。
Let's go to slide 9 and our updated outlook for the full year. At our Investor Day in September, we estimated 2026 stand-alone operating EBITDA of about $1.3 billion. Today, we are updating that estimate to a range of $1.1 billion to $1.125 billion for the full year.
接著請看第9頁投影片,以及我們更新後的全年展望。在9月的投資人日,我們估計2026年獨立口徑的營運EBITDA約為13億美元。今天,我們將該估計更新為全年11億至11.25億美元的區間。
The update reflects the realities of Brazil, where the pressures described earlier have intensified and we are still seeing negative developments in the local market. Our outlook now reflects all of that. We now expect lower price and volume in Brazil compared to our prior outlook, driven by channel inventory normalization, weather and weaker grower profitability.
此次更新反映了巴西的現實情況:先前描述的壓力已加劇,我們仍看到當地市場出現負面發展。我們的展望現已將上述因素全數納入考量。相較於先前展望,我們目前預期巴西的價格與銷量將更低,主因為通路庫存正常化、天候因素以及種植戶獲利能力轉弱。
We are not assuming any meaningful improvement in purchasing behavior in Brazil for the rest of the year, and we estimate that the full year EBITDA impact related to elevated channel inventory is approximately $100 million.
我們不假設巴西在今年剩餘期間的採購行為會有任何顯著改善,並估計與通路庫存偏高相關的全年EBITDA影響約為1億美元。
On that basis, full year operating EBITDA is expected to be down 12% versus last year at the midpoint, with operating EBITDA margin of about 15% for the year. This would imply a fourth quarter EBITDA that is now expected to be about half of 2025 levels on an adjusted pro forma basis, given the significance of Brazil to our fourth quarter results.
在此基礎上,按中位數計算,全年營運EBITDA預期將較去年下降12%,全年營運EBITDA利潤率約為15%。鑑於巴西對我們第四季業績的重要性,這意味著第四季EBITDA在調整後備考口徑下,現預期約為2025年水準的一半。
On operating EPS, we expect full year to be in the range of $0.76 to $0.80 per share, up about 3% at the midpoint, helped by lower operating income tax expense when compared to the adjusted pro forma period last year.
在營運EPS方面,我們預期全年每股介於0.76至0.80美元,中位數約成長3%,主要受惠於相較去年調整後備考期間,營運所得稅費用較低。
Now clearly, this is a meaningful change from expectations. But what I don't want to get lost is how the rest of the business is performing outside of Brazil. We are executing well in a tough market, and we are controlling what we can control. Productivity savings are on track for the year. And apart from separation-related items such as higher IT costs, we are managing SG&A spending tightly.
顯然,這與原先預期相比是一次重大的變動。但我不希望大家忽略巴西以外其他業務的表現。在艱困的市場中,我們執行得當,並且把可控的事情控制好。今年的生產力節省進度符合預期。此外,除與分拆相關的項目(例如較高的IT成本)外,我們也嚴格控管SG&A支出。
With that, let me turn it back to Luke for some final key takeaways before we move to Q&A.
接下來,我把時間交回給Luke,請他在進入問答前做最後幾點重點總結。
Luther Kissam - Chief Executive Officer
Luther Kissam - Chief Executive Officer
Thanks, Jeff. Let me close with three points. First, as shown by the growth in new product sales, our innovation strategy is working and our pipeline is as good as any in the industry. It's clear that farmers will invest in differentiated solutions when it creates value for them.
謝謝你,Jeff。我用三點作結。第一,如新產品銷售成長所示,我們的創新策略正在奏效,我們的研發管線在業界不輸任何同業。很明顯,當差異化解決方案能為農民創造價值時,他們就會願意投資。
Second, it's a tale of different markets. North America, EMEA and Asia all delivered organic growth in the quarter, performing as expected. Brazil disappointed. Some of that was caused by the overall market conditions and some was caused by our elevated inventory levels from the last growing season.
第二,這是一個關於不同市場的故事。北美、EMEA 與亞洲在本季皆實現有機成長,表現符合預期。巴西令人失望。部分原因來自整體市場狀況,部分原因則是我們上一個生長季留下的偏高庫存水位。
I expect the inventory levels in Brazil to be at a more acceptable level by the end of their growing season, but that will weigh on our fourth quarter results. Our leadership team is focused on finding the best structure for us to remain competitive in Brazil while meeting our profit expectations. We'll keep you updated on that progress.
我預期巴西的庫存水位在其生長季結束前會回到較可接受的水準,但這將對我們第四季業績造成壓力。我們的領導團隊正專注於尋找最佳架構,使我們在巴西維持競爭力的同時,也能達成我們的獲利預期。我們會持續向各位更新相關進展。
Third, we are focused on controlling matters within our control, such as cost of goods sold, productivity and spending. Earlier this month, we kicked off work with a third-party to critically examine our cost structure and ways in which we can operate more efficiently.
第三,我們專注於管控我們可控的事項,例如銷貨成本、生產力與支出。本月稍早,我們與第三方啟動合作,嚴謹檢視我們的成本結構,以及我們能以更高效率營運的方式。
As I said in September, we simply cannot afford the infrastructure we inherited. We are looking at our processes. Infrastructure, working capital levels, complexity, and where technology and automation can make us more efficient from a cost and from a cash perspective. It's very early days, but I am optimistic about the opportunities.
正如我在九月所說,我們根本無法負擔我們承接下來的基礎架構。我們正在檢視我們的流程。包括基礎架構、營運資金水位、複雜度,以及科技與自動化如何從成本與現金的角度讓我們更有效率。目前仍在非常早期的階段,但我對這些機會感到樂觀。
I also want to understand how much of the opportunity we capture versus reinvest behind accelerating growth of differentiated products. But what is clear is that cost actions will certainly need to be taken. So we know what we have to do, keep innovating, drive productivity, make sure our channel inventory levels are appropriate and take cost and complexity out of the business. Outside of Brazil, this business is doing what it's built to do. In Brazil, we're managing through a tough market the right way. That will remain our focus. I look forward to your questions.
我也想了解,我們能捕捉多少機會、相較之下又會有多少再投資,用於加速差異化產品的成長。但很明確的是,成本行動勢必需要採取。因此,我們知道該做什麼:持續創新、提升生產力、確保通路庫存水位適當,並降低業務的成本與複雜度。除巴西以外,這項業務正如其設計般運作。在巴西,我們正以正確方式度過艱困市場。這仍將是我們的重點。我期待各位的提問。
Rafael Soares - Head of Investor Relations
Rafael Soares - Head of Investor Relations
Now let's move on to your questions. I would like to remind you that our cautions on forward-looking statements and non-GAAP measures apply to both our prepared remarks and the following Q&A.
現在我們進入提問時間。我想提醒各位,我們對前瞻性陳述與非 GAAP 衡量指標的注意事項,適用於我們的事先準備發言以及接下來的問答。
Operator, please provide the Q&A instructions.
接線員,請提供問答環節的說明。
Operator
Operator
We will now begin the question-and-answer session. (Operator Instructions)
我們現在開始問答環節。(接線員說明)
Vincent Andrews, Morgan Stanley.
Vincent Andrews,摩根士丹利。
Vincent Andrews - Analyst
Vincent Andrews - Analyst
Thank you and good morning, everyone. Luke, wondering if I could just ask you, do you think it's appropriate to think about it this way? If we were to bifurcate your business between Brazil and then everywhere else, would it be fair to say that everywhere else was still operating within a reasonable band of the outlook, the multi-year outlook you provided at the Analyst Day, but it's Brazil where we have to reassess what the earnings power is on a go-forward basis. Do you think that's a fair framework for this point in time?
謝謝,各位早安。Luke,我想請教一下,這樣理解是否合適?如果我們把你們的業務拆分為巴西與其他所有地區,是否可以說其他地區仍在你們於分析師日提供的多年期展望之合理區間內運作,但巴西則是我們必須重新評估未來的獲利能力(earnings power)?你認為以目前時間點來看,這是個合理的分析框架嗎?
Luther Kissam - Chief Executive Officer
Luther Kissam - Chief Executive Officer
Yes, Vincent, I do think that's a fair framework. If you look, we had growth in each of the other three world areas in spite of this see the core pricing headwinds that we saw in North America. I feel like we're on target for those areas and Brazil is the major weak spot. And we're going to see that, unfortunately, the selling season in Brazil is the third and fourth quarters and that's what we've got going in and we've got a lot of work to do there to fix it.
是的,Vincent,我認為這是個合理的框架。如果你看,我們在其他三個全球區域都實現成長,儘管北美面臨我們所看到的核心定價逆風。我覺得那些區域都在軌道上,而巴西是主要的弱點。而且不幸的是,巴西的銷售季在第三與第四季,我們正處於那個期間,還有很多工作要做來把它修正。
Operator
Operator
Chris Parkinson, Wolfe Research.
Chris Parkinson,Wolfe Research。
Chris Parkinson - Equity Analyst
Chris Parkinson - Equity Analyst
Great. Thank you so much. I just want to take a step back on the Acetochlor and the effects on North American pricing and what's going on in the aggregate portfolio. I'm aware that two of the major European competitors had kind of competing products, one direct, one indirect in terms of that classification of the herbicide market. They took action and you acted in a consequence.
很好。非常感謝。我想先退一步,談談 Acetochlor 以及其對北美定價的影響,還有整體產品組合的情況。我知道兩家主要的歐洲競爭對手有某種程度上相互競爭的產品,一個是直接競品、另一個是間接競品,就除草劑市場分類而言。他們採取了行動,而你們也因此做出回應。
When I think about the cadence of those effects in your portfolio, the balance of this year and more importantly into 2027, what can you do to actually mitigate that? Are you getting prices in other areas of your portfolio? Is there anything in terms of selling patterns and when that's actually built in the channel and then ultimately distributed to the farmers? What clarity can you give us to make sure that we get that right into 2027? Thank you so much.
當我思考這些影響在你們產品組合中的發生節奏、今年剩餘期間以及更重要的到 2027 年,你們實際上能做些什麼來緩解?你們是否在產品組合的其他領域取得價格?在銷售模式方面,是否有任何因素與通路何時建立庫存、以及最終何時分銷到農戶有關?你們能提供哪些清晰資訊,確保我們對 2027 年的判斷是正確的?非常感謝。
Luther Kissam - Chief Executive Officer
Luther Kissam - Chief Executive Officer
Yeah. Hey, that's a great question. As I said in September, we're going to see a year-over-year price decline in North America related to Cedecor in the third quarter and the fourth quarter. We'll also see a little bit of it in the first quarter, but then the second quarter of 2027, it'll be, I would say, minimal where we are today. So the way you ought to look at it is we'll see about the same amount as we saw in the third quarter, in the fourth quarter, maybe a little bit more, but right around that same amount would be my anticipation and then it will taper off into the first quarter and taper off again into the second quarter of 2027.
是的。這是個很好的問題。如我在九月所說,我們將在北美於第三季與第四季看到與 Cedecor 相關的年對年價格下滑。第一季也會看到一點,但到 2027 年第二季,以我們目前所見,我會說影響將非常有限。因此你應該這樣看:第四季大約會看到與第三季差不多的影響,可能略多一些,但我預期大致相當;接著在 2027 年第一季會逐步減弱,到了 2027 年第二季會再進一步減弱。
What we're able to do there is we actually got some additional volume across that, we've got new product sales that are driving good productivity there, they were up. I think 20% in the third quarter and year-to-date volume and new product sales were up 14% and they've taken some cost action in North America. So taking some good action there, but you're right that we'll see it again in the fourth quarter, less in the first of '27 and even less in the second quarter of '27.
我們能做的是,實際上我們在該領域取得了一些額外的銷量;我們也有新產品銷售帶動良好的生產力提升,表現上升。我想第三季成長了 20%,而年初至今的銷量與新產品銷售成長了 14%,同時北美也採取了一些成本行動。所以那邊正在採取一些良好措施;但你說得對,我們在第四季仍會再看到影響,2027 年第一季較少,2027 年第二季更少。
Operator
Operator
Kevin McCarthy, Vertical Research Partners.
Kevin McCarthy,Vertical Research Partners。
Kevin McCarthy - Analyst
Kevin McCarthy - Analyst
Yes, thank you very much. I was wondering if you might comment on the level of destocking in the channel for crop protection chemicals versus lower pounds on the ground as they say in the jargon. In other words, were the end users applying fewer pounds of product or is it strictly a channel inventory management issue and might that answer vary by region?
是的,非常感謝。我想請你評論一下,作物保護化學品在通路端去庫存(destocking)的程度,相較於業界術語所說的「地面用量(pounds on the ground)」下降。換句話說,終端用戶是否施用更少的產品用量?還是這純粹是通路庫存管理的問題?而且這個答案是否會因地區而異?
Luther Kissam - Chief Executive Officer
Luther Kissam - Chief Executive Officer
So it would certainly vary by region, significantly by region. So let's talk about Brazil since that's the problem spot, Kevin, just for a second. If you look year-to-date, the sellout market in Brazil is down roughly 12%, which would be the equivalent of $1 billion.
這當然會因地區而異,而且差異很大。Kevin,我們先談巴西,因為那是問題點。如果看年初至今,巴西的終端銷售(sellout)市場大約下滑 12%,相當於 10 億美元。
So the sellout is not occurring in Brazil like it has in the past, number one. If you look at market data, the black box data through the end of September, Corteva has not lost share in the Brazilian market. Our own the farm applications are good. And I want to be really clear, Kevin, I'm talking about own farm applications, okay? So we're maintaining share at the farm gate.
所以第一,巴西的終端銷售不像過去那樣發生。如果看市場數據,截至九月底的黑盒子數據顯示,Corteva 在巴西市場並未流失市占。我們自身的農場端施用情況良好。Kevin,我想非常清楚地說,我指的是自有農場端施用(own farm applications),好嗎?因此我們在農場端(farm gate)維持市占。
But what we are seeing is, we had more inventory in the Brazilian channel than maybe others did. I don't quite know what all they had, but what I can tell you is we think we had roughly $250 million of revenue more in 2020 coming out of 2025 growing season coming into this and we can't sell more into the channel.
但我們看到的是,我們在巴西通路端的庫存可能比其他人更多。我不太清楚他們各自的庫存狀況,但我能告訴你的是,我們認為相較之下,我們大約多了 2.5 億美元的營收——從 2025 年生長季結束延續到這一季——而我們無法再向通路賣進更多。
Now, there are other things we could do, let's be clear. I could give credit terms to some of the distributors down there, but they're already past due. And if they're already past due, it's not good business sense to give more credit. So I'm not doing that. So we lost some opportunities there. We could get extended payment terms that people are asking for.
現在,我們還可以做其他事情,先把話說清楚。我可以給下面一些經銷商提供信用條件,但他們已經逾期了。而如果他們已經逾期,再給更多信用在商業上並不合理。所以我不會那麼做。因此我們在那裡失去了一些機會。我們也可以提供人們所要求的延長付款條件。
I'm not willing to go out really past the crop seasoning given payment terms. I don't think that's a good business model, so we're not doing that. And look, I could try to take and there are other places to sell product. I could push product into North America, into Europe and other places like that. That's not the right way to run the business and that's not how we're going to run this business.
我不願意把付款條件拉得遠遠超過作物季節。我不認為那是好的商業模式,所以我們不會那麼做。另外,你看,我也可以嘗試把產品賣到其他地方。我可以把產品推到北美、歐洲以及其他類似地區。那不是經營企業的正確方式,也不是我們要用來經營這家公司的方式。
All it does is take a problem that is in Brazil and expands it to other areas of the world, and I'm not willing to do it. So we've taken the position that we're going to take our medicine in Brazil and go forward. But if you look around the rest of the world, we don't see that same type of stocking that we've seen in Brazil. So I'm not as concerned about that in 2027. And we really got to focus on it now.
那樣做只會把原本在巴西的問題擴散到世界其他地區,而我不願意這麼做。所以我們的立場是:我們會在巴西把該吞的苦果吞下去,然後繼續往前走。但如果你看看世界其他地區,我們沒有看到像巴西那樣的囤貨情況。所以我對 2027 年這方面沒有那麼擔心。而我們現在確實必須把重點放在這件事上。
There is a lot of closer to just-in-time ordering. And one of the issues we have is so much of our revenue, a disproportionate portion of our revenue comes in the last 10 days of the quarter. And that's the way the business has always operated. It's mind-numbing, but that's what happens.
現在有很多訂單更接近即時(just-in-time)下單。而我們面臨的其中一個問題是:我們的營收中有很大一部分、而且是不成比例的一部分,集中在季度最後 10 天。而這一直是這個業務的運作方式。這讓人難以置信,但事情就是這樣發生。
And so, I don't believe that we've got an issue in inventory anywhere else outside of Brazil. We've seen that, we've taken steps to address it. I believe that the inventory levels will be back to where they traditionally would be in Brazil by the end of their current growing season.
因此,我不認為除了巴西以外的任何地方存在庫存問題。我們已經看到這個情況,也採取了措施來處理。我相信到巴西目前這一季作物生長季結束時,庫存水位會回到其傳統應有的水準。
Jeff Rudolph - Chief Financial Officer
Jeff Rudolph - Chief Financial Officer
Kevin, it's Jeff. Just to be clear, to add on to Luke's comments, when you think about the change in our guide for the full year, it is 100% Brazil driven, right? There's not other areas of the market we're seeing softness that we're tucking into that reduction for the full year, the roughly, call it, $200 million of EBITDA. It is really the incremental or I should say reduced volume expectations coming out of Brazil because of this channel matter aligned with Luke's comments and what we said in our prepared remarks about half of that $200 million will be tied to that. And the other $100 million is because of other market weakness, including further price erosion that we're seeing in that market that is widespread. So just to be very clear, it is a Brazil concentrated issue.
Kevin,我是 Jeff。為了說清楚一點,補充 Luke 的評論,當你看我們對全年指引的變動時,這 100% 是由巴西所驅動,對吧?我們沒有把其他市場看到的疲軟也塞進這次全年下修裡;大約、可以說約 2 億美元的 EBITDA 下修,實際上是因為巴西這個通路問題導致的增量——或者我應該說是下調的——出貨量預期,這與 Luke 的評論一致,也與我們在事先準備的發言中所說的相符,其中約一半的 2 億美元會與此相關。另外的 1 億美元則是因為其他市場的疲弱,包括我們在該市場看到的進一步價格侵蝕,而且這種情況相當普遍。所以非常清楚地說,這是一個高度集中在巴西的問題。
Luther Kissam - Chief Executive Officer
Luther Kissam - Chief Executive Officer
And to add onto that, the price that we're seeing in Brazil, 80% of the price headwinds in Brazil are related to five products. So it's a handful of products in Brazil on price. It is our inventory levels that we had coming out of 2025 are what are driving the problems in Brazil for the second-half of the year.
再補充一點,我們在巴西看到的價格方面,巴西 80% 的價格逆風都與五個產品有關。所以在巴西的價格問題主要集中在少數幾個產品。而我們在 2025 年結束時所帶出的庫存水位,正是驅動今年下半年巴西問題的原因。
Operator
Operator
Jeff Zekauskas, JPMorgan.
Jeff Zekauskas,摩根大通。
Jeffery Zekauskas - Analyst
Jeffery Zekauskas - Analyst
Thanks very much. You talked about the price pressure in North America coming from the acetochlor. In the quarter, that would have been about, I don't know, $65 million. You think that there's the same thing in the fourth quarter, so that's $130. What's the size of the acetochlor business? And why doesn't it affect the second quarter of next year since your price decrease seems to have begun in this quarter?
非常感謝。你提到北美的價格壓力來自乙草氯(acetochlor)。在本季度,那大概會是——我不知道——約 6,500 萬美元。你認為第四季度也會有同樣情況,那就是 1.3 億美元。乙草氯這個業務的規模有多大?以及為什麼它不會影響明年第二季度,因為你的降價似乎是在本季度開始的?
Jeff Rudolph - Chief Financial Officer
Jeff Rudolph - Chief Financial Officer
Jeff, hey, it's Jeff here. Good question, right? So I think your math is pretty close. For the third quarter, the call it $120 million price headwind that we experienced, roughly half of that is US acetochlor driven, so about $60 million. For the fourth quarter, right, we are going to see, call it another step down in overall pricing from third quarter into fourth quarter.
Jeff,你好,我是 Jeff。好問題,對吧?我認為你的計算相當接近。第三季度我們經歷的、約 1.2 億美元的價格逆風,其中大約一半是由美國乙草氯所驅動,也就是約 6,000 萬美元。至於第四季度,我們將會看到整體定價從第三季度到第四季度再下調一個台階。
A lot of that's driven by Brazil, but there is going to be headwind in fourth quarter, excuse me, related to acetochlor, but not at the $60 million level, closer to that $40-ish million level and obviously that is going to be factored in our guide right now.
其中很大一部分是由巴西所驅動,但第四季度也會有與乙草氯相關的逆風,不過不會到 6,000 萬美元的程度,會更接近約 4,000 萬美元左右;而且很明顯,這已經納入我們目前的指引之中。
We get into next year, we're not going to see as much of that because our third quarter impact reflected some of the adjustment where we were through the year, right? So we're going to have a little bit of that in terms of year-over-year in the first quarter, but once we get to second quarter, we're going to be mostly trued up with what the price is at the channel level and we shouldn't be facing year-over-year headwinds. We've looked at this a bunch of different ways, you're asking the same questions that we've asked the team a dozen times and we feel good about that and it's largely calibrated in terms of how I just described it.
到了明年,我們不會看到那麼多這方面的影響,因為第三季度的影響已反映了我們在年內所做的一些調整,對吧?所以在第一季度的年對年比較上,還會有一點點這方面的影響;但一旦到了第二季度,我們基本上就會與通路層級的價格水準對齊(trued up),也就不應該再面臨年對年的逆風。我們用很多不同方式檢視過這件事;你問的問題跟我們對團隊問了十幾次的是同樣的問題,我們對此很有把握,而且大致上就是依照我剛才描述的方式來校準。
Operator
Operator
Joel Jackson, BMO Capital Markets.
Joel Jackson,BMO 資本市場。
Joel Jackson - Equity Analyst
Joel Jackson - Equity Analyst
Hi, good morning. Thanks for doing the call. Luke, you talked very strongly in your prepared remarks, I believe, maybe some of the Q&A answer too about needing to address Brazil, needing to address cost infrastructure. I understand you're just starting to engage third parties, but can you give us a flavor of some of the things that you're thinking about to give us an idea of what you can do over the next year or two to address the things you're talking about? Thanks.
嗨,早安。謝謝舉辦這通電話會議。Luke,你在事先準備的發言中——我想——以及可能在部分問答回覆中也非常強調,需要處理巴西問題、需要處理成本基礎設施。我理解你們才剛開始聘請第三方,但你能否讓我們大致了解一下你正在思考哪些事情,好讓我們對你在未來一到兩年能做些什麼來處理你所談到的問題有個概念?謝謝。
Luther Kissam - Chief Executive Officer
Luther Kissam - Chief Executive Officer
Yes. So I'll tell you, as of right now, we've got a hiring freeze, so we're not hiring new people. We've got a spending -- we've tightened down SG&A spending. You can see that in the third quarter. We are looking to prioritize projects. Rather than apply 80% of the cost and spreading that across all the projects, what we're doing is some of the projects that we have, for instance, in R&D, we're going to slow down for a year.
可以。我先告訴你,就目前而言,我們已經實施凍結招募,所以不再聘用新員工。在支出方面——我們已收緊 SG&A(銷售、一般及行政)支出。你可以在第三季度看到這一點。我們正在優先排序各項專案。與其把 80% 的成本攤到所有專案上,我們現在做的是:對於我們的一些專案,例如在研發(R&D)方面,我們會放慢一年。
We're going to take a year off, we're going to put them on the shelf, and then we're going to really focus on the one so that our spending is focused and delivers the biggest bang for our bucks in that short period of time. So we're making priority decisions. As you look longer-term, the way in which we work, this infrastructure has to change.
我們會暫停一年,把它們先擱置,然後真正聚焦在那一個(或少數幾個)專案上,讓我們的支出更集中,並在短期內帶來最高的投入產出效益。所以我們正在做優先順序的決策。從更長期來看,我們的工作方式、這套基礎設施必須改變。
We need to simplify our processes, we need to stop doing some things, and we need to work our process is just with a white sheet of paper and change the way that we think about doing it. Once we do that and simplify it, we can put technology and AI on the top of it to further drive our cost down to further gain better insight. So it's not going to happen in a quarter. That's something that transformation is going to take place over the next four to six to eight quarters, right?
我們需要簡化流程,需要停止做某些事情,並且需要以一張白紙重新檢視我們的流程,改變我們對如何執行的思維方式。一旦我們做到這點並加以簡化,就可以在其上導入科技與 AI,進一步降低成本並取得更好的洞察。所以這不會在一個季度內發生。這樣的轉型將會在接下來四到六到八個季度內逐步展開,對吧?
But I also know I've got costs that I've got to go look at for the fourth quarter as well as for early next year. And we've got -- we're in process to looking at that, and we'll share more about that with you at our next earnings call.
但我也知道,第四季以及明年年初我還有一些成本必須去檢視。我們正在著手評估,並會在下一次財報電話會議上與各位分享更多細節。
Operator
Operator
David Begleiter, Deutsche Bank.
David Begleiter,德意志銀行。
David Begleiter - Analyst
David Begleiter - Analyst
Thank you. Good morning. Luke, on acetochlor, anymore color on your US strategy going forward? I know Brazil is a tough market, but maybe it is there's a path forward for US acetochlor. Thank you.
謝謝。早安。Luke,關於乙草氯(acetochlor),能否再多談一些你們未來在美國的策略?我知道巴西市場很艱難,但也許美國的乙草氯仍有一條可行的前進路徑。謝謝。
Luther Kissam - Chief Executive Officer
Luther Kissam - Chief Executive Officer
Yeah, I think you could see that the US, we took a big hit in the quarter and our acetochlor volumes were fine. If you looked at that, we're very competitive in the market, we'll continue to be competitive in the market. Our price in the US on acetochlor is as good as anybody's. So I'm not worried about our strategy long-term for acetochlor. We've got the volume. We'll have programs with our dealers where there's a demand we'll be able to sell through on that.
是的,我想你可以看到,美國在本季受到很大衝擊,但我們的乙草氯銷量(出貨量)其實還不錯。如果你看這一點,我們在市場上非常有競爭力,也會持續保持競爭力。我們在美國的乙草氯定價不輸任何人。所以我不擔心乙草氯長期策略。我們有量。我們會與經銷商推出方案,在有需求的地方,我們能把產品順利銷售出去。
And we've got other products and new products in the pipeline that we'll be able to package with acetochlor to give us a real competitive package for growers that I think the distribution is going to like. So I think they've got a good strategy there. But we're managing through the life cycle of that product. That's been a product that's been around for a long time, and we've got to manage through that cycle.
而且我們還有其他產品與新產品在研發管線中,可以與乙草氯一起打包,為種植戶提供一套真正具競爭力的組合,我認為通路也會喜歡。所以我認為他們在那方面有很好的策略。但我們也在管理這個產品的生命週期。這是一個存在很久的產品,我們必須在這個週期中妥善管理。
So I feel good about where we are with that. I also think that in North America, you can look at what they did in the third quarter. They overcame that and still were able to grow their market. So I feel good about where we are in North America. I actually feel good about where we are everywhere in the world and the methods that they're using, the products they are doing, their interaction with growers, the new product growth that we're seeing everywhere in the world, we got a problem in Brazil that we got to fix. So I'm not.
所以我對我們目前的狀況感到樂觀。我也認為,在北美,你可以看看他們第三季的表現。他們克服了那些因素,仍然能夠擴大市占。所以我對北美的狀況感到樂觀。其實我對我們在全球各地的狀況都感到樂觀——他們採用的方法、正在推動的產品、與種植戶的互動,以及我們在全球各地看到的新產品成長;我們在巴西有個問題必須解決。所以我不會——
That is going to be my focus. What do we do in Brazil, how do we get more effective down there, how do we get more efficient so that we can be in what is a very important agricultural market and at the same time make money and the profitability that we and our stakeholders expect us to make in that country?
那將會是我關注的重點。我們在巴西要怎麼做?如何在那裡變得更有效?如何提升效率,讓我們能在一個非常重要的農業市場中立足,同時也能賺錢,並達到我們以及利害關係人期望我們在該國達成的獲利水準?
Operator
Operator
Matthew Dio, Bank of America.
Matthew Dio,美國銀行。
Matthew Dio - Analyst
Matthew Dio - Analyst
Look, Luke, I mean, everyone at Corteva is obviously focused on growth, and I don't want to seem reactionary. But like simplistically, is Brazil a market you need to compete in longer-term? And I know normalized revenue basis is a big volume market, but from like a return on capital, time, cash conversion, is it worth it? Some of your broader ag peers are saying maybe it's not. And maybe that's too much, right? Or would you fast track just product exit? You mentioned five key products there causing a lot of headwinds, but do you have to be there in that capacity?
Luke,我的意思是,Corteva 的每個人顯然都專注於成長,我也不想顯得反應過度。但簡單來說,從長期看,巴西是一個你們必須參與競爭的市場嗎?我知道以常態化營收來看那是一個高量市場,但從資本報酬、時間、現金轉換的角度,它值得嗎?你們一些更廣泛的農業同業正在說也許不值得。也許這樣問太重了,對吧?或者你們會加速推進產品退出?你提到有五個關鍵產品造成很大的逆風,但你們必須以那樣的規模留在那裡嗎?
Luther Kissam - Chief Executive Officer
Luther Kissam - Chief Executive Officer
Yeah. So I think that is the very question that I've asked, okay? Let's be clear. I'm not going to do anything if we can't make money. We're not. We're in the business of making money. We're in the business of growth. We're in the business of delivering returns for our shareholders. And if we can't do something toward that goal, we're not going to do it.
是的。所以我認為這正是我問過的問題,好嗎?我們講清楚。如果我們賺不到錢,我不會做任何事。我們不會。我們做的是賺錢的生意。我們做的是成長的生意。我們做的是為股東創造報酬。如果某件事無法朝這個目標前進,我們就不會做。
Now one of the issues that you have to face on that is you got to look at all the data. That is a big volume country for herbicides and crop protection products. If you are out of that product and you don't have that volume, what does that do to your cost in other areas of the world for those similar products? And are you competitive?
不過其中一個你必須面對的問題是,你得看所有數據。那是一個除草劑與作物保護產品的高量國家。如果你退出那個市場、沒有那個量,這會如何影響你在世界其他地區同類產品的成本?你還有競爭力嗎?
Now, so then you go down a step, it's okay, well, if you need to be in that country for a whole lot of reasons. Do we have the right structure in place, do we need the infrastructure that we have down there, is there another way to go to market, do we go direct, we go to co-ops, we go through distribution, do we need all of that, what is the right approach, what's the right sales approach, so the question that you just asked me has been asked of the team, okay?
接著你再往下推一步:好,如果基於很多原因你需要在那個國家。那我們是否有正確的組織架構?我們是否需要目前在那裡的基礎設施?是否有其他進入市場的方式?我們要直銷嗎?走合作社嗎?透過經銷通路嗎?我們需要全部都做嗎?正確的做法是什麼?正確的銷售方式是什麼?所以你剛剛問我的問題,我已經拿去問團隊了,好嗎?
And we have to go in and look at it in a methodical way, not get emotional, not be reactionary and pull all that data apart so that we understand if we push the balloon over here, where does it pop out over there and how do we do that? But I want you to have the confidence that we are leaving no stone unturned in that market and any other market.
我們必須以有系統的方法進去檢視,不要情緒化,不要反應式決策,把所有數據拆開來分析,這樣我們才能理解:如果我們把氣球在這邊壓下去,它會在那邊鼓起來——會產生什麼連鎖影響,以及我們要怎麼做。但我希望你有信心:在那個市場以及任何其他市場,我們都不會放過任何一個可能性。
Operator
Operator
Kristen Owen, Oppenheimer.
Kristen Owen,奧本海默。
Kristen Owen - Analyst
Kristen Owen - Analyst
Hi, good morning. Thank you for the question. Maybe help me with what's happening on the biological side. I think I can understand a lot of the channel dynamics happening with traditional crop chem, but I tend to think about this being a product line where you don't get a lot of that destock/restock. So can you maybe walk us through if there was some knock-on effect that impacted, biologicals or just some additional color there would be helpful. Thank you.
嗨,早安。謝謝讓我提問。也許可以幫我理解一下生物製劑(biologicals)這邊發生了什麼事。我覺得我能理解傳統作物化學品通路端的很多動態,但我通常認為這條產品線不太會出現那種去庫存/補庫存的波動。所以你能否帶我們走一遍:是否有一些連帶效應影響到生物製劑?或提供更多背景會很有幫助。謝謝。
Luther Kissam - Chief Executive Officer
Luther Kissam - Chief Executive Officer
Yeah, let me start it real high and then I'll turn it over here to Jeff and Brooke. But first of all, a disproportionate portion of our biologicals was in Brazil. So when Brazil takes the hit that it did, biologicals take a similar hit at a high level. And then Jeff or Brooke, one of y'all.
好的,我先從高層次說明,然後我會把問題交給 Jeff 和 Brooke。首先,我們生物製劑中有不成比例的一大部分是在巴西。所以當巴西像這次一樣受到衝擊時,從高層次來看,生物製劑也會受到類似的衝擊。接著 Jeff 或 Brooke,你們其中一位。
Jeff Rudolph - Chief Financial Officer
Jeff Rudolph - Chief Financial Officer
Yeah, hey, Kristen. You're right. I mean, we look at the numbers in the quarter, obviously, volumes were down and they were also down year-to-date. And as Luke said, it's really a Brazil issue. And as you recall, with the acquisitions we did a few years ago to really establish ourselves as a market leader in this space, we have a large concentration to the Latin America market, right, which is a good thing because it's where we're seeing some of the best adoption rates in the industry.
是的,嗨,Kristen。你說得對。我們看本季的數字,顯然量下滑,而且年初至今也下滑。如 Luke 所說,這主要是巴西的問題。而且你還記得,我們幾年前透過收購來真正建立我們在這個領域的市場領導地位,因此我們在拉丁美洲市場的曝險(集中度)很高,對吧?這其實是好事,因為那裡是我們看到全產業採用率最好的地區之一。
But what it does is it exposes us to market dislocations that we're experiencing right now across the industry. So when we see sell out or POG slowing down versus last year, it's going to impact our volumes too, so everything kind of slows down.
但這也讓我們暴露在目前全產業正在經歷的市場錯位之下。所以當我們看到終端銷售(sell-out)或 POG 相較去年放緩時,也會影響到我們的出貨量,因此整體就會一起放慢。
So we have some timing, but certainly biologicals are not immune to the market forces, so you have a lot of considerations at the form level around investment choices and this may be a nice to have versus a need to have in some cases, but this is where differentiation really comes in. And we have products like Utrisha that has established itself pretty strongly across many crops in that market and we're seeing really good growth and it's part of our growth expectations for that business going forward, especially in Brazil and generally has strong margins to it, so there's flexibility in that business, but right now the volume issue.
所以有一些時點因素,但可以確定的是,生物製劑並非不受市場力量影響;在農場層面,關於投資選擇有很多考量,在某些情況下,這可能屬於「有更好」而非「非要不可」。但這也正是差異化發揮作用的地方。我們有像 Utrisha 這樣的產品,已在該市場的多種作物上建立了相當強的地位,我們看到非常好的成長,它也是我們未來對該業務成長預期的一部分,特別是在巴西;而且通常毛利率也很強,因此該業務具有彈性,但目前主要還是量的問題。
Again, is tied to this Brazil dynamic that we're managing through. I wouldn't say it's necessarily a destocking issue, but it's more of a slowdown in demand versus our expectations just given where that market is. And you'll see in our year-to-date numbers, there's a North America headwind. I wouldn't get too caught up in that.
再次強調,這與我們正在管理的巴西市場動態有關。我不會說這必然是去庫存的問題,但更多是需求相較於我們預期出現放緩,主要取決於該市場目前的狀況。而你會在我們年初至今的數據中看到,北美帶來了一些逆風。我不會太過糾結在那一點上。
It's a smaller part of our business. It's obviously an important area for us to grow, especially as we see some of the newer technology we have coming out and Utrisha being part of that. But again, it's a small part of our business. I wouldn't get too hung up on the volume. So we're really talking about a Brazil issue.
那只是我們業務中較小的一部分。這顯然是我們很重要的成長領域,尤其是當我們看到一些較新的技術即將推出,而 Utrisha 也是其中一部分。但再說一次,它在我們業務中占比不大。我不會對出貨量太過執著。所以我們真正談的是巴西的問題。
Operator
Operator
Patrick Cunningham, Citi.
Patrick Cunningham,花旗。
Patrick Cunningham - Analyst
Patrick Cunningham - Analyst
Hi, good morning. Thanks for taking my question. Maybe just a follow-up on Matt's previous question. As you think about [acetochlor's] approaching off-patent, do you see the sustainability of peak revenue being a much shorter time cycle than it has been in the past? And do you see the balance shifting toward discontinuing and divesting products versus where you're deciding to defend against generics through lower unit cost and adjusting pricing?
嗨,早安。謝謝讓我提問。我想延續 Matt 前一個問題追問一下。當你們思考乙草氯(acetochlor)即將專利到期時,你們是否認為營收高峰的可持續性會比過去短得多?另外,你們是否看到策略重心會轉向停產與出售產品,而不是透過降低單位成本與調整定價來對抗學名藥?
Luther Kissam - Chief Executive Officer
Luther Kissam - Chief Executive Officer
Yeah, I think that you have to look at that because the day if you got any volume at all, the day after the patent expires, the generics are going to be there. There is excess capacity from a production standpoint in low-cost countries that are going to be ready to come in. So you've got to be ready in a shorter period of time, you don't have a tail anymore after that patent expires. So you got to find intuitive ways to manage that life cycle how it relates to mixtures or blends or things like that a pure active ingredient doesn't have.
是的,我認為你必須這樣看:只要你還有任何銷量,專利到期的隔天,學名藥就會出現。從生產角度來看,低成本國家存在過剩產能,隨時準備切入。所以你必須在更短的時間內做好準備,專利到期後就不再有尾端效益。因此,你得找到更有創意的方法來管理生命週期,例如與混配、複配等相關的做法,因為純有效成分本身不具備這些手段。
So you've got to come with the formulations and to drive the value for the grower and that's what we'll do. I think also the ability to blend that with a package with something from our microbial platform or something from our biologicals platform as we bring those together will give us the opportunity to do that, but we've got to execute and we're going to have a shorter winter to execute, which means we've got to drive our costs down even further, not only the further the cost down of operating, but how long it takes us and the cost of bringing that molecule to the market, we've got to shorten the time and reduce the cost.
所以你必須推出配方,並為種植戶創造價值,這就是我們會做的事。我也認為,當我們把它與我們的微生物平台或生物製劑平台中的產品打包、進行複配時,會給我們帶來這樣的機會;但我們必須執行到位,而且我們可執行的時間窗口會更短,這意味著我們必須進一步降低成本——不僅是營運成本要更低,將該分子推向市場所需的時間與成本也要下降;我們必須縮短時間並降低成本。
So again, that means we're going to have to stop doing some things that we've been doing. And we can't let perfect get in the way of really good. And that's what we're going to have to do. That's part of what the transformation workout is going to identify. But you hit the nail on the head, shorter window of time to get those profits out of there. So you've got to drive your costs down to improve your ROI. And you've got to use lifecycle management with our entire portfolio to extend that as long as we can.
所以再說一次,這代表我們必須停止做一些我們一直在做的事情。我們不能讓「追求完美」妨礙「做到很好」。這就是我們必須採取的做法。這也是轉型工作將要識別的一部分。但你說得很對:能把利潤拿出來的時間窗口更短了。所以你必須降低成本以提升投資報酬率(ROI),並且要用整體產品組合的生命週期管理,盡可能延長這段時間。
Operator
Operator
Lucas Beaumont, UBS.
Lucas Beaumont,瑞銀。
Lucas Beaumont - Analyst
Lucas Beaumont - Analyst
Thank you. Good morning. So I just kind of wanted to think about sort of what the reduced sort of second-half outlook here means as we head into next year. Volume growth has sort of come in softer, pricing is down five single-digits sort of exiting the year. I mean, that probably seems to imply that we're going to see continued pricing pressure into next year now, at least low single-digits.
謝謝。早安。我想從你們下調下半年展望來思考,這對我們進入明年意味著什麼。銷量成長偏弱,價格在年底時下滑約 5 個百分點(單位數)。我的意思是,這似乎暗示明年仍會面臨持續的價格壓力,至少是低個位數的下滑。
Maybe we'll recover a little bit of that on the cost side, I guess, if raw materials are sort of better or lower as a bit of an offset. But I mean, unless you're sort of expecting much stronger volume growth somewhere, I mean, it seems like flat to up low single-digits on EBITDA now would probably be a win into 2027.
我想,若原物料狀況改善或價格更低,或許能在成本端回收一點,作為部分抵銷。但除非你們預期某些地方的銷量成長會明顯更強,否則看起來到 2027 年,EBITDA 持平到低個位數成長可能就算是勝利了。
I'd sort of be pointing to something, I mean like the $1.11 billion to $1.15 billion range. Is that the right way to frame the setup or could you kind of talk us through anything we're missing? Thanks.
我大概會指向像是 11.1 億到 11.5 億美元的區間。這樣的框架是否正確?或者你們能否帶我們梳理一下是否有我們遺漏的部分?謝謝。
Luther Kissam - Chief Executive Officer
Luther Kissam - Chief Executive Officer
Yes, so there are a lot of give and takes. And I believe we will grow in 2027. That's what I believe. Some of it's going to be cost, some of it's going to be volume. And we'll see a little bit of Brazil in the first quarter as they go through the end of their growing season, but I expect Brazil from a year-over-year comparison in '27 over the second-half ought to be a little better than they are in '26 because remember, we're having a little extra downside in Brazil because of the level of inventory that we had in the channel.
是的,這裡面有很多此消彼長的因素。而我相信我們在 2027 年會成長。這是我的看法。其中一部分來自成本,一部分來自銷量。而在第一季,巴西還會有一些影響,因為他們正走到生長季的尾聲;但我預期以年對年比較來看,2027 年相較 2026 年下半年,巴西的表現應該會好一些,因為請記得,我們在巴西還有額外的下行壓力,原因是通路中的庫存水位偏高。
So assuming we get the inventory where it ought to be by year end, by the end of their growing season, we ought to be in a good spot to be able to recover some of that in 2027. So that's the goal. So I think we will be able to grow the business in 2027, but I need to see all the roll-ups. We need to see what cost actions we can take and we will share that with you in February when we do our fourth quarter earnings call, but I do expect us to grow in '27.
所以假設我們能在年底、也就是他們生長季結束前,把庫存調整到應有水位,那麼我們在 2027 年就會處於有利位置,能夠收復其中一部分。這就是目標。因此我認為我們在 2027 年能夠讓業務成長,但我需要看到所有彙總結果。我們需要看看能採取哪些成本行動;我們會在二月第四季財報電話會議時與各位分享,但我確實預期我們在 2027 年會成長。
Jeff Rudolph - Chief Financial Officer
Jeff Rudolph - Chief Financial Officer
And maybe, Lucas, on pricing specifically, right? So if you think about the updated full-year guide, it's going to say pricing is in that down mid to high single-digit range now for the business, given some of these pressures that we had talked about.
另外,Lucas,特別談到定價,對吧?如果你看更新後的全年指引,考量到我們剛才談到的一些壓力,現在整體業務的定價大概會落在中到高個位數的下滑區間。
And aligned with Luke's comments, 80% of that is the US acetochlor issue and these five molecules in Brazil that we're talking about. So you got to feel that we're better positioned in the market given how those prices have come down this year, so it would have to be a real step change in terms of other competitor aggressive action to bring down competing technology and that's not our expectation right now.
而且呼應 Luke 的評論,其中 80% 來自美國乙草氯(acetochlor)問題,以及我們正在談的巴西這五個分子。所以你應該會覺得,鑑於今年價格已經下來,我們在市場上的定位更好;除非其他競爭對手採取非常激進的行動、在競爭技術上出現「階躍式」降價,但這不是我們目前的預期。
So then the next question is, what are generics doing, right? Over the past year plus, we've seen steady decline in prices coming out of China for generic molecules. As we're sitting here today, I never want to say the tides have turned, but we are saying, I'll call it, selective stabilization, right, and some of that is raw material driven, et cetera.
接下來的問題就是:學名藥在做什麼,對吧?在過去一年多,我們看到中國出口的學名藥分子價格持續下滑。以我們今天所見,我從不想說趨勢已經反轉,但我們看到的是——我稱之為——選擇性地趨於穩定,而其中一部分是由原物料驅動等等。
So obviously, pricing in Brazil are still the uncertainties we're watching, but when you think about where we face pressure this year more disproportionately and greater risk coming out of maybe generics, generally speaking, out of China, I think we've covered some of that in the comments we've made, but I just want to give that context.
所以很明顯,巴西的定價仍是我們在觀察的不確定因素;但當你思考今年我們面臨的壓力更不成比例、以及可能來自學名藥(整體而言主要是中國)的更大風險時,我認為我們在先前的評論中已經涵蓋了一部分,只是我想補充這個背景。
Operator
Operator
Frank Mitsch, Fermium Research.
Frank Mitsch,Fermium Research。
Frank Mitsch - Analyst
Frank Mitsch - Analyst
Thank you and good morning. During the prepared remarks, you mentioned that you're going to, you're you're on track to year-end cash position of $1.5 billion. Now you're at $1.8 billion in cash at the end of the third quarter. I'm assuming that that $1.5 billion end of year that you're on track for is a net cash position. And just in general, what your free cash flow expectations are for 4Q and for 2027? Thank you.
謝謝,早安。在事先準備的發言中,你提到你們年底現金部位可望達到 15 億美元。但第三季末你們的現金是 18 億美元。我假設你所說的年底可望達到 15 億美元,是指淨現金部位。另外更一般地,你們對第四季以及 2027 年的自由現金流(FCF)預期為何?謝謝。
Jeff Rudolph - Chief Financial Officer
Jeff Rudolph - Chief Financial Officer
Hey, Frank, it's Jeff. So you're right, we finished the quarter, excuse me, on a pro forma basis around $1.8 billion of cash. We expect still to be close to about $1.5 billion in terms of our cash position by the end of the year. So that's not net cash, I'm just talking cash, right? And you can see the debt levels we have in our schedules, right?
嗨,Frank,我是 Jeff。所以你說得沒錯,我們在本季結束時——不好意思——以備考(pro forma)基礎計算,現金約為 18 億美元。我們仍預期到年底,我們的現金部位大約會接近 15 億美元。所以那不是淨現金,我只是指現金,對吧?而且你可以在我們的附表中看到我們的負債水準,對吧?
It's a line to call it around $1 billion of financial debt that we're targeting by year-end and we're kind of close there today, right? So how we go from where we are today to the year-end, obviously, it would say we're going to have a use of cash in the fourth quarter. Historically speaking, this business has generated a modest amount of cash in the fourth quarter. There's a few things going on in our results that's causing a use of cash.
我們的目標是在年底把金融負債控制在大約 10 億美元左右,而我們目前其實已經相當接近了,對吧?所以從我們現在的位置走到年底,顯然意味著第四季會有現金流出。從歷史來看,這項業務在第四季通常會產生小幅的現金流入。但我們的業績中有幾個因素正在造成現金的使用。
One is, we have a lower level of prepayment and early pay coming in North America in the fourth quarter, call it in between $100 million and $150 million lower than last year, so that's causing a headwind and that was done at our discretion, we're right sizing just to let that level coming in based on affordability levels, so no concern or pause there, we're controlling that based on where we see the right level for the business and for where we are.
其中之一是,北美在第四季的預付款與提前付款水準較低,約比去年少 1 億到 1.5 億美元,因此形成逆風;而這是我們自行決定的,我們是在做規模調整(right sizing),讓流入水準依可負擔性水準而定,所以這裡沒有任何疑慮或需要停下來觀望,我們是依我們認為對業務與我們現況而言的適當水準來加以控制。
We're going to have higher AR, obviously, just with the timing of some of our sales. So that's going to be a slight headwind. So from a cash flow from operations, you can expect a use of cash in the fourth quarter. Our CapEx is generally going to be aligned to what we said on a run rate basis in our September comments around $200 million a year. So call it on an underlying basis about $50 million of CapEx just from the run and maintain.
另外,因為部分銷售時點的關係,我們的應收帳款(AR)會提高。所以這也會帶來些微逆風。因此,就營運活動現金流而言,你可以預期第四季會是現金流出。我們的資本支出(CapEx)大致會與我們在 9 月評論中所說的年化約 2 億美元的水準一致。所以以基礎面來看,僅就維持營運(run and maintain)而言,CapEx 約為 5,000 萬美元。
Now there's some lingering CapEx we have for the separation. I will come through, but not meaningful, that will take that number up slightly. So and we have a safe to pay our dividends. So we feel good about how we're tracking toward that $1.5 billion and the teams are executing well. I'm encouraged by how we finished third quarter on managing working capital, all things considered.
另外,我們還有一些與分拆相關、尚未完全結束的 CapEx。我會把它納入考量,但金額不大,會讓該數字略微上升。此外,我們也有足夠能力支付股利。所以我們對於朝 15 億美元目標的進度感到放心,團隊執行得很好。綜合各項因素來看,我對第三季在營運資金管理上的收尾表現感到鼓舞。
So what does that mean for '27? This business should still generate cash flow conversion aligned with what we had said at Investor Day, right? And what we feel good about is that, there's still opportunity to drive working capital efficiency. Now I'm not going to commit anything today. Obviously, we want to see how the year finishes and how some of these key markets play out.
那對 2027 年意味著什麼?這項業務仍應能產生與我們在投資人日所說一致的現金流轉換率,對吧?而我們有信心的是,仍有機會提升營運資金效率。不過我今天不會做任何承諾。顯然,我們想先看看年底的收官情況,以及一些關鍵市場的發展。
But there's opportunity because we're at higher levels on a DSO basis. There's more opportunity to work with Ralph and team on driving our inventory levels. So there's levers there we can pull, but let's continue to navigate some of this competitive dynamic we're facing in the market that is driving some of our AR. But overall, cash conversion in this business should be fairly aligned to how we've talked about it up to this point.
但確實有機會,因為我們在應收帳款週轉天數(DSO)方面處於較高水準。也有更多機會與 Ralph 及其團隊合作,推動庫存水準的改善。所以我們有一些槓桿可以拉動,但我們也要持續因應市場上我們面臨的競爭態勢,這正在推升我們部分的應收帳款。總體而言,這項業務的現金轉換應會與我們迄今的說法大致一致。
Operator
Operator
Edlain Rodriguez, Mizuho.
Edlain Rodriguez,瑞穗(Mizuho)。
Edlain Rodriguez - Analyst
Edlain Rodriguez - Analyst
Thank you. Good morning, everyone. I think going to your financial framework for the next three years, like you had a component in there for share repurchase. Can you tell us like what you think, what are you thinking about in terms of that, like the pace that, yes, like what you're thinking in terms of share repurchase for next year and within that three-year period?
謝謝。各位早安。我想回到你們未來三年的財務框架,你們裡面有一個組成項目是股票回購。你能否談談你們對此的想法,例如回購的節奏——是的——也就是你們對明年以及這三年期間內股票回購的規劃想法?
Luther Kissam - Chief Executive Officer
Luther Kissam - Chief Executive Officer
Yeah, so I think obviously at this price, I'm very interested in buying back stock and I think that will be as good a return as any that we're going to get for our use of cash. We've got an outstanding authorization to buy back stock and what I have in the fourth quarter is, the structure of the spend and the representations made in connection with that separation from a tax standpoint create certain near-term capital allocation constraints for me where I just don't have the ability to buy back in the fourth quarter, but buybacks will certainly be a part of our 2027 cash deployment priorities.
是的,所以我想很明顯,在這個價格水準下,我非常有興趣回購股票,而且我認為就現金使用而言,這會是我們能取得的回報中不輸任何其他選項的一個。我們目前有一項尚未用完的股票回購授權。而我在第四季面臨的是:從稅務角度來看,與該次分拆相關的支出結構與所做的陳述,對我造成了一些短期的資本配置限制,使我在第四季沒有能力進行回購;但回購肯定會是我們 2027 年現金運用優先事項的一部分。
Operator
Operator
Arun Viswanathan, RBC Capital Markets.
Arun Viswanathan,RBC 資本市場(RBC Capital Markets)。
Arun Viswanathan - Analyst
Arun Viswanathan - Analyst
Great. Thanks for taking my question. Most of my questions have been answered, but I guess maybe I can just ask on maybe some partnership opportunities. I know that there's been fungicide and opportunities on that side. How does that kind of contribute to your '27 and '28 outlook? Are there other opportunities outside of Fluindapyr or what else are we expecting on that side? Thanks.
很好。謝謝讓我提問。我的大部分問題都已經被回答了,但我想也許可以問一下合作夥伴機會。我知道在殺菌劑方面有一些合作與機會。這類合作對你們 2027 年與 2028 年的展望會有什麼貢獻?除了 Fluindapyr 之外,還有其他機會嗎?或在那一端我們還能期待什麼?謝謝。
Luther Kissam - Chief Executive Officer
Luther Kissam - Chief Executive Officer
So yeah, I think longer-term, we're going to look at ways we can work together with universities, start-ups, competitors to have the technology so that we can share those products and bring them to the market sooner at a lower cost than we can. And we'll look at other deals like we have rimisoxafen. That will obviously be another opportunity there and opportunities that we have like that will do. Having anything come to bear in '27 or '28 is a little tough. Those are longer-term deals.
所以是的,我認為從長期來看,我們會尋找能與大學、新創公司、競爭對手合作的方式,取得相關技術,讓我們能共享這些產品,並以更低成本、更快把它們推向市場。我們也會尋找其他像 rimisoxafen 這樣的交易。那顯然也會是另一個機會,以及我們手上類似的機會都會去做。至於要在 2027 或 2028 年就看到成果落地,會有點困難。那些是較長期的交易。
But strategically, when we look at how we transform and what our transformation office, that's something that we'll certainly be looking at and opportunities for ways to go. Pretty clear at Investor Day and everybody I've talked to, we're open for business. So anybody who's got an opportunity out there that and maybe we have products that just don't quite make the cut for us for what we want to do.
但在策略上,當我們看待如何轉型,以及我們的轉型辦公室在做什麼時,這肯定是我們會去評估的方向與機會。在投資人日以及我交談過的每一位人士那裡都很清楚,我們對外是開放合作的。所以任何人如果手上有機會——而且也許我們有一些產品,對我們想做的事情而言並不完全符合門檻。
And we're going to look to license those because we've got a great portfolio. We're going to license things that aren't as meaningful for us, but may be meaningful for other people and they may be able to have a better go at it than we will. So we're going to look at ways that we can take any step necessary to reduce. Our costs and increase our bottom line.
我們就會考慮把那些產品授權出去,因為我們有很棒的產品組合。我們會把對我們而言不那麼重要、但對其他人可能很重要的東西拿去授權,對方也許能比我們做得更好。所以我們會尋找各種方式,採取任何必要步驟來降低我們的成本並提高我們的獲利底線。
Operator
Operator
Ben Theurer, Barclays.
Ben Theurer,巴克萊(Barclays)。
Benjamin Theurer - Analyst
Benjamin Theurer - Analyst
Yeah, good morning and thanks for taking my question. I was wondering if we could talk a little bit about some of the drivers that you've laid out about two months ago as it relates to like cost improvements, et cetera.
是的,早安,謝謝讓我提問。我想知道我們是否可以再談談你們大約兩個月前提出的那些驅動因素,特別是與成本改善等相關的部分。
Are there any other ways or other areas where you're looking at aside from improvement in productivity, maybe on the sales side, whatever reviewing. Just anything where you think either within COGS or within SG&A that you see opportunity to take cost out of the system? Thank you.
除了提升生產力之外,你們是否還在看其他方式或其他領域,例如銷售端或其他檢視項目。也就是任何你們認為在銷貨成本(COGS)或銷售、一般及管理費用(SG&A)中,仍有機會把成本從系統中移除的地方?謝謝。
Luther Kissam - Chief Executive Officer
Luther Kissam - Chief Executive Officer
Yeah, everything is on the table. I don't really know how else to say it, we're looking at COGS everywhere we can, are we producing as effectively and efficiently as we can, are we producing in the right places, are we formulating in the right places, do we have the right logistical channels to get to where we need to be, are there certain countries, are there certain products that we just need to overall exit that don't make sense.
是的,一切都在檯面上。我不知道還能怎麼說:我們在所有可能的地方檢視 COGS——我們是否以最有效、最高效率的方式生產?我們是否在正確的地點生產?我們是否在正確的地點進行配方製造?我們是否有正確的物流通路把產品送到需要去的地方?是否有某些國家、某些產品,我們整體上就是需要退出,因為不合理。
Is the infrastructure that we have in the country effective enough or do we need to either add to it or do we just need to switch and sell straight through distribution, not have sales on the ground? How are we going to compete whenever we have a biological or a differentiated product versus a commodity chemical that we're selling here? It can't do the same.
我們在國內所擁有的基礎設施是否已足夠有效,還是我們需要擴充,或者我們只需要轉換模式,直接透過經銷通路銷售,而不需要地面銷售團隊?當我們在這裡銷售的是生物性或差異化產品,而對手是大宗化學品時,我們要如何競爭?它不可能做到一樣。
So what are the different routes that we have to market? What are we in the back office? Where are we less. Than we should be. What are the things that we've done in the past that we really don't is nice to have, but not something that we have to absolutely have in order to do it. So look, if you're not making it and you're not selling it, we're looking to see what we need to do to reduce our costs.
那麼,我們有哪些不同的上市路徑?我們後勤/後台(back office)做了哪些?我們在哪些方面不足。低於我們應該達到的水準。過去我們做過哪些事情,其實只是「有了更好」,但並非我們為了做到這件事而必須絕對具備的?所以你看,如果你不在生產、也不在銷售,我們就要檢視需要做什麼來降低成本。
Operator
Operator
Salvatore Tiano, KeyBanc Capital Markets.
Salvatore Tiano,KeyBanc Capital Markets。
Salvatore Tiano - Analyst
Salvatore Tiano - Analyst
Can you hear me now?
你現在聽得到我嗎?
Operator
Operator
Yes.
是的。
Salvatore Tiano - Analyst
Salvatore Tiano - Analyst
Perfect. Just want to ask a couple of things about your financials. So firstly on Q4, obviously, you have the implied guidance and you have also the implied revenue, I guess, which should be around $2 billion, $2.1 billion. That's just a low mid-single-digit decline year-on-year. So it implies 7%, 8%, 9% maximum EBITDA margin in Q4. So obviously, understandable that there's pressure in Brazil, but how do we reconcile that actually sales are not really declining substantially?
太好了。我想問幾個關於你們財務數字的問題。首先關於第四季,顯然你們有隱含的指引,也有隱含的營收,我想大約會在 20 億美元、21 億美元左右。這只是年減低到中個位數的幅度。因此它隱含第四季 EBITDA 利潤率最高約 7%、8%、9%。所以很明顯可以理解巴西有壓力,但我們要如何解釋:其實銷售並沒有大幅下滑?
They're actually the sales decline is decelerating versus Q3, yet you're seeing that 50% EBITDA. And secondly, can you clarify a little bit your cash position? You were at $1.8 billion in Q3, but the pro forma Q2 results were at $3.1 billion cash. And at least from what we've seen now with the pro forma balance sheet, it looks like your working capital is pretty much the same. It looks like the only thing you've paid down is $400 million in pension. So where did the other $800 million in cash go in Q3?
實際上,相較第三季,銷售下滑正在放緩,但你們卻看到那 50% 的 EBITDA(變動)。第二點,你能否更清楚說明一下你們的現金部位?你們第三季是 18 億美元,但備考(pro forma)的第二季結果顯示現金為 31 億美元。而且至少從我們現在看到的備考資產負債表來看,你們的營運資金幾乎相同。看起來你們唯一償還的是 4 億美元的退休金。那第三季另外 8 億美元的現金去哪裡了?
Jeff Rudolph - Chief Financial Officer
Jeff Rudolph - Chief Financial Officer
Hey, Sal, it's Jeff. So on Q4, with our updated our guide for the year, it would imply a Q4 that's around, call it, $2 billion of revenue, which would be on a pro forma basis down year over year. And it's 100% price, right? And volumes, I would say, are expected to be generally flat year-over-year in the fourth quarter. So pricing is really the main driver.
嗨,Sal,我是 Jeff。關於第四季,依照我們更新後的全年指引,隱含第四季營收大約是 20 億美元;以備考基礎來看,將會年減。而且這 100% 來自價格,對吧?至於銷量,我會說第四季預期大致與去年同期持平。所以價格才是真正的主要驅動因素。
So what that means is we got pricing in the fourth quarter that's implied to be down high single-digit. So when prices are down that level, you're going to have a disproportionate impact to your EBITDA and your EBITDA margin, and that's why we're seeing that step change in terms of our implied guide for fourth quarter and why the margin is more impacted than you might expect just from a normal price and volume relationship. So hopefully that makes sense.
這代表第四季隱含的定價將下滑到高個位數。當價格下滑到那個幅度時,對 EBITDA 與 EBITDA 利潤率會造成不成比例的影響;這也是為什麼我們在第四季隱含指引上看到那樣的階梯式變化,以及為什麼利潤率受到的影響會比你僅從一般價格與銷量關係所預期的更大。希望這樣說得通。
On cash, I don't want to get too much into the pro forma of Q2 to Q3. There's a lot of moving parts in terms of just how the financing was executed for the two companies in the separation. We can certainly go through that more details with the IR team and refer you to our SEC filings where we've tried to lay that out as best as we can.
至於現金,我不想在這裡過度深入討論備考口徑下第二季到第三季的變化。因為在兩家公司分拆過程中,融資執行方式有很多變動因素。我們當然可以和投資人關係(IR)團隊更詳細地說明,也可以請你參考我們的 SEC 申報文件,我們已盡可能在其中把這些內容交代清楚。
But in terms of where we are today, we're at $1.8 billion of cash at the end of the quarter and we're on a path to the $1.5 billion that we committed to as part of our Investor Day and I'm confident that we've got good control around our working capital, teams are exercising good discipline there, we saw it in our third quarter results and looking forward to showing you more details on that.
但就我們目前的狀況而言,本季末現金為 18 億美元,我們正朝著在投資人日所承諾的 15 億美元目標前進。我有信心我們對營運資金有良好控管,各團隊在這方面也維持良好紀律;我們在第三季結果中已看到,並期待之後向各位提供更多細節。
Now you have to appreciate, with the separation and pro forma results, cash flow is one of the most impacted areas in terms of complexity, right, in balance sheet. So we're going to have to work through this here as we go quarter to quarter, but we're focused on the level of cash we're going to deliver at the year-end and we feel good about the path we're on.
你也必須理解,在分拆與備考結果之下,現金流在資產負債表中是受複雜性影響最大的領域之一,對吧?因此我們必須在接下來逐季推進的過程中把這些釐清,但我們聚焦的是年底要交付的現金水位,而且我們對目前所走的路徑感到樂觀。
Operator
Operator
Jeff Zekauskas, JPMorgan.
Jeff Zekauskas,摩根大通(JPMorgan)。
Jeffery Zekauskas - Analyst
Jeffery Zekauskas - Analyst
Thanks very much. Do you have other problematic molecules that will come off patent over the coming two years that are not part of the handful of molecules that you're talking about now? And secondly, were there negative weather effects in the quarter that affect your EBTI globally?
非常感謝。在未來兩年內,是否還有其他具問題性的分子會失去專利保護,但不在你們目前提到的那幾個分子之列?第二,這一季是否有不利的天氣因素影響你們全球的 EBTI?
Luther Kissam - Chief Executive Officer
Luther Kissam - Chief Executive Officer
So there's nothing major that comes off in two years within by the end of '28, Jeff. We have some that come off in the early '30s, but we've got new products that we're launching in '28 and then some in the early '30s too. So again, we're going to have to balance, we're going to have to launch the ones that we're bringing on effectively and we're going to have to manage the down cycle of some of them that will be coming off that patent protection, okay?
Jeff,在兩年內、也就是到 2028 年底之前,沒有什麼重大的專利到期。我們有一些會在 2030 年代初期到期,但我們也會在 2028 年推出新產品,並且在 2030 年代初期也會推出一些。所以再說一次,我們必須取得平衡:要有效地推出我們即將導入的產品,同時也要管理其中一些在專利保護到期後所面臨的下行週期,好嗎?
The weather, El Nino had an impact in Brazil. Europe was drier and Southeast Asia was had some weather issues, but all of that stuff we would overcome. I mean, it didn't cause us where we are, but it all caused us to overcome. And we could -- we would have dealt with that within the quarter without any problem.
天氣方面,聖嬰現象(El Nino)對巴西造成了影響。歐洲較為乾燥,東南亞也有一些天氣問題,但這些我們都能克服。我的意思是,它並不是造成我們目前狀況的原因,但確實增加了我們需要克服的因素。而且我們本來就能在本季內處理好,沒有任何問題。
Operator
Operator
We have reached the end of the Q&A session. I will now turn the call back to Rafa Soares for closing remarks.
問答環節到此結束。我現在把電話交回給 Rafa Soares 作結語。
Rafael Soares - Head of Investor Relations
Rafael Soares - Head of Investor Relations
Thank you for our interest in Corteva. Be safe.
感謝各位對 Corteva 的關注。請注意安全。
Operator
Operator
This concludes today's call. Thank you for attending. You may now disconnect.
今天的電話會議到此結束。感謝各位出席。您現在可以掛線。